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Introduction
Since tuberculosis was declared a global emergency in 1993 by the 
World Health Organization (WHO), new cases of tuberculosis 
and deaths from the disease have dropped dramatically in several 
countries with a high burden of the disease.1 All six WHO regions 
are on track to meet the Millennium Development Goal target 
of reducing tuberculosis incidence and deaths from tuberculosis 
by half between 1990 and 20151,2 and, with the sole exception 
of the African Region, all are on track to halve tuberculosis 
mortality rates.2 Nevertheless, the situation remains precarious.3 
Twenty-two predominantly low- and middle-income countries 
were estimated to account for 82% of the 5.7 million tuberculosis 
cases notified in 20101 and high rates of death from tuberculosis 
among people living with human immunodeficiency virus (HIV) 
infection prevail in much of sub-Saharan Africa.4,5
Rapid case identification of individuals with sputum 
smear-positive tuberculosis and rapid initiation of anti-tuber-
culosis chemotherapy are key to controlling tuberculosis6 and 
are promoted as part of the DOTS strategy model of passive 
case-finding that has been adopted by most national tubercu-
losis programmes (NTPs).7 From the patient’s perspective, the 
tuberculosis diagnostic and care pathway (Fig. 1) begins with a 
recognition of symptoms that prompt care seeking. Individuals 
may drop out of care during the diagnostic process (“loss to 
follow-up during diagnostic period”), before initiating treat-
ment (“pre-treatment loss to follow-up”, formerly known as 
“initial default”) or after treatment has begun. Patients diag-
nosed with smear-positive tuberculosis who do not initiate 
treatment represent an important failing in the provision of 
care.8,9 High rates of mortality are reported in this group.10 
Moreover, bringing these patients into care could reduce tu-
berculosis transmission to others.11 Patients with a diagnosis 
of tuberculosis who are lost to follow-up before they receive 
treatment are not included in routine reporting by NTPs. Thus, 
programme effectiveness may be overestimated.8
Efforts to improve tuberculosis case detection rates have 
centred on ensuring rapid treatment for all individuals diag-
nosed with smear-positive tuberculosis.12,13 With this goal in 
mind, WHO has recently changed its policy, which now calls 
for two sputum specimens instead of three and same-day col-
lection.13,14 However, assessing the impact of these changes on 
linkage to treatment has been hampered by a lack of understand-
ing of the extent of pre-treatment loss to follow-up8 and of the 
patient, provider and health system factors that contribute to it.15
Although nearly 50 years have passed since high rates of 
pre-treatment loss to follow-up were first identified as a po-
tential major contributor to the failure of tuberculosis control 
programmes, researchers and policy-makers have paid little 
attention to the fate of patients who do not access treatment 
after receiving a diagnosis of tuberculosis.16,17,18 Indeed, the “Piot 
model” used to describe loss to care at different stages for any 
disease was first developed for tuberculosis.18
This study had two main objectives: (i) to systematically 
quantify pre-treatment loss to follow-up in low- and lower-
middle income countries and in countries with a high burden 
of tuberculosis; and (ii) to describe the reasons for drop-out and 
the outcomes seen in individuals with a tuberculosis diagnosis 
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who do not initiate treatment. A second-
ary objective was to assess the quality of 




We followed PRISMA reporting guide-
lines for systematic reviews.19 To define 
the points at which tuberculosis patients 
drop out of care, we developed the tu-
berculosis diagnostic and care pathway 
described in Fig. 1 using terms recom-
mended recently that replace previously 
used terms such as “initial default”.9
For this study, patients in a national 
tuberculosis care programme who re-
ceived a diagnosis of tuberculosis on 
the basis of at least one positive sputum 
smear or culture but did not start tuber-
culosis treatment were defined as having 
pre-treatment loss to follow-up. This 
included individuals who died before 
initiating treatment.
The recruitment period was defined 
as the time during which patients with a 
diagnosis of tuberculosis were recruited 
to studies or during which data from 
such patients were extracted from na-
tional programme registers. For studies 
with individual follow-up, the follow-up 
period was defined as the time between 
diagnosis and the most recent date of 
active follow-up. For studies in which 
tuberculosis treatment registers were 
checked retrospectively, we present the 
minimum and maximum follow-up 
periods available. Because studies had 
different follow-up periods and varying 
temporal definitions for pre-treatment 
loss to follow-up, we used the definition 
given in each study rather than a time-
delineated definition. However, we did 
require a follow-up period of at least 
4 weeks to allow enough time for patients 
to link to care and treatment.
Fig. 1. The diagnostic and care pathway for tuberculosis

























Pre-treatment loss to 
follow-up
Lost to follow-up, on 
treatment
Table 1. Systematic strategy used to search for studies on pre-treatment loss to follow-
up in tuberculosis patients
Set MEDLINE Global Health
1 tuberculosis tuberculosis
2 TB patient refusal of treatment
3 TUBERCULOSIS dropout
4 Sets 1–3 were combined with “OR” dropouts
5 PATIENT DROPOUT referral
6 DELAYED DIAGNOSIS delayed
7 REFERRAL AND CONSULTATION attrition
8 DIAGNOSTIC SERVICES retain
9 TUBERCULOSIS, PULMONARY DIAGNOSIS treatment programme
10 initial delay* initial delay
11 initial default* initial default
12 drop out retention
13 attrition diagnostic delay
14 retention treatment delay
15 retain* care seeking
16 diagnostic delay* loss to follow-up
17 treatment delay* lost to follow-up
18 treatment seek* Sets 2–17 were combined with “OR”
19 care seek* Sets 1 and 18 were combined with “AND”
20 loss to follow-up Set 19 was limited to 1994–2013
21 lost to follow-up
22 loss to follow-up
23 lost to follow-up
24 Sets 1–23 were combined with “OR”
25 Sets 4 and 24 were combined with “AND”
26 Set 25 was limited to 1994–2013 
Note: Words written in capital letters were used as MeSH headings; the others were used as free text. The 
asterisks are the truncation symbol in Medline (i.e. any possible ending after the preceding text).
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Inclusion and exclusion criteria
Studies were included in the review if 
they reported on the proportion of pa-
tients having smear- or culture-positive 
tuberculosis who experienced pre-
treatment loss to follow-up in NTPs in 
low- or lower-middle-income countries 
as defined by the World Bank on 1 July 
2011,20 or in any of the 22 countries 
with a high burden of tuberculosis as 
defined by the Stop TB department of 
WHO.1 Studies that reported on clinical 
trials, including randomized and non-
randomized active case-finding studies, 
were excluded because participants in 
these studies would be more likely to re-
ceive intensive follow-up and tracing and 
would not be representative of patients 
with tuberculosis diagnosed routinely. 
Studies that reported only on paediatric 
patients – i.e. children 15 years of age or 
younger – were excluded. Studies that 
recruited both adults and children were 
included even if the data were not disag-
gregated by age group.
Search strategy
We systematically searched the Ovid, 
Medline and Global Health databases 
for studies published between 1 Janu-
ary 1994 and 31 January 2013. Our 
search strategy is outlined in Table 1. 
We also hand searched the abstracts of 
the Union World Conference on Lung 
Health from 2009 to 2012. We identified 
additional studies through reference lists 
and annotated bibliographies and by 
corresponding with researchers in the 
field. If the manuscript did not give the 
absolute number of individuals with pre-
treatment loss to follow-up, we contacted 
the authors to obtain the data.
Three authors (KK, PM, RH) re-
viewed titles and abstracts to obtain the 
full texts of relevant articles. All three 
assessed the full texts to determine their 
suitability and based their final inclusion 
in the review on consensus as a team. PM 
and KK extracted data from included 
studies using a pre-designed table.
Quality of selected studies
One researcher (PM) used a modified 
version of the Newcastle-Ottawa scale 
to assess studies in terms of quality and 
of the risk of bias in the selection of 
participants and in the ascertainment of 
outcomes. Each study could score up to 
six points in each of these two categories, 
each having six items. The section for 
the selection of comparison groups was 
removed from the Newcastle-Ottawa 
scale because no study had a comparison 
group. The factors considered included: 
the representativeness of the patients 
recruited with respect to the underlying 
population of tuberculosis patients diag-
nosed in the routine health-care system; 
the test used to ascertain the diagnosis of 
tuberculosis; the method of identification 
of pre-treatment loss to follow-up; and 
the adequacy of follow-up (judged in 
terms of the proportion of participants 
whose outcomes were ascertained, with 
> 85% being adequate). In studies in 
which laboratory and treatment registers 
were linked, we evaluated the process 
and variables used for linkage (including 
personal identifiers and dates).
Data analysis and statistical 
methods
For each included study, we report on 
the number of patients who received a 
diagnosis of smear- or culture-positive 
tuberculosis and the proportion who 
initiated antituberculosis treatment. For 
patients identified as having experienced 
pre-treatment loss to follow-up, we 
report the duration of follow-up and, 
if available, the proportion who were 
successfully traced and their outcomes 
(alive but not on treatment; alive after 
starting treatment; deceased; or trans-
ferred to another facility but treatment 
and vital status unknown). To calculate 
summary estimates of pre-treatment loss 
to follow-up, we classified as treatment 
initiators those tuberculosis patients 
who were classified as having experi-
enced pre-treatment loss to follow-up 
but who, on tracing, were found to have 
initiated treatment at an alternative site. 
We assessed heterogeneity using the I2 
statistic. On initial analysis, we found 
substantial heterogeneity between stud-
ies. Therefore, we estimated the pooled 
proportion of patients with a diagnosis 
of tuberculosis and pre-treatment loss to 
follow-up (and the corresponding 95% 
confidence intervals) using a random-
effects model, weighting for the inverse 
of the variance and stratification by study 
region. Stata 12.1 (Statacorp, College 
Station, Texas, USA) was used to analyse 
the data.
Fig. 2. Flowchart for the selection of studies on pre-treatment loss to follow-up in 
patients with a diagnosis of tuberculosis 
Records identified through database 
searching: 
Total (n = 5096)
Medline: (n = 2668)
Global Health: (n = 1106)
IUTBLD Conferences: (n = 1322)
Additional records identified
through other sources (n = 5)
Records after duplicates 
removed (n = 5088)
Records excluded (n = 4942)
Not relevant (n = 4698)
Not low-or-middle income/high tuberculosis 
burden 
country (n = 139)
Only patients already on tuberculosis treatment 
recruited (n = 38)
Only paediatric cases (n = 12)
Only MDR-TB patients (n = 16)
Other reasons (qualitative data, 
review article) (n = 39)
Full-text articles excluded (n = 123)
No data on pre-treatment 
loss to follow-up (n = 48)
Only patients already on tuberculosis treatment 
recruited (n = 68)
Qualitative data only (n = 3)
Modelling/commentry (n = 3)
Duplicate data (n = 1)
Duplicates excluded (n = 13)
Records screened 
(n = 5088)
Full-text articles assessed for 
eligibility (n = 146)
Studies included in qualitative 
synthesis (n = 23)
Studies included in quantitative 





















IUTBLD, International Union Against Tuberculosis and Lung Disease; MDR-TB, multidrug resistant-
tuberculosis.
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We identified 5096 potentially relevant 
studies, of which 23 were eligible for in-
clusion in the analysis (Fig. 2).10,21–42 These 
reported on a total of 34 706 patients with 
smear- or culture-positive tuberculosis, 
3474 of whom had experienced pre-treat-
ment loss to follow-up. The characteristics 
of the included studies are summarized 
in Table 2. There were 13 studies from 
sub-Saharan Africa (8 countries), 9 from 
Asia (5 countries) and 1 from the western 
Pacific (1 country).
Most studies reported on pre-treat-
ment loss to follow-up among smear-
positive patients only. Two studies 
included patients who were either 
smear- or culture-positive.29,30 In some 
studies smear positivity was defined as 
at least  125,27,28,30,35,41,42 or at least 222–24,34 
positive smears, whereas others did not 
provide any definition.10,21,26,31–33,36–40 A 
study from South Africa stratified rates 
of reported pre-treatment loss to follow-
up by smear status (smear-positive or 
smear-negative but culture-positive),23 
whereas another study, also from South 
Africa, reported on pre-treatment loss to 
follow-up in tuberculosis patients whose 
diagnosis was established clinically and/
or bacteriologically.29
Quality of included studies
The quality of the included studies var-
ied (Table 3). Only a few studies (n = 4) 
showed a low risk of bias or scored full 
marks across all items assessing patient 
selection and ascertainment of out-
comes. The methods for ascertaining 
pre-treatment loss to follow-up were 
suboptimal or poorly described in most 
studies; only seven studies adequately 
described the follow-up period allotted 
to each participant. The majority of stud-
ies (n = 19) identified patients diagnosed 
with tuberculosis by extracting data 
from laboratory or sputum collection 
registers (Table 2). Such extraction was 
performed retrospectively in 17 studies 
and prospectively in two. In the remain-
ing 4 studies, patients with a diagnosis 
of tuberculosis were identified as part 
of ongoing epidemiological surveil-
lance30 or were prospectively recruited 
for follow-up from a chest clinic33,40 or 
from primary-health-care centres.41 
The recruitment periods ranged from 
3 months24,34,36 to 90 months.30 Only 
9 studies22–25,27,29,31,36,37 applied a cut-off 
for time since diagnosis – ranging from 
1 month to 3 months – to define pre-
treatment loss to follow-up.
Although most studies (n = 16) used 
retrospective linkage of laboratory and 
treatment registers to identify patients 
who initiated treatment for tuberculo-
sis10,21–29,32,37–39,41,42 – and so scored full 
marks for this item – the quality of the 
procedures used to ensure accurate 
linkage varied considerably. Only one 
study27 described the variables used to 
link records and gave the proportion of 
records that were reliably matched.
Pre-treatment loss to follow-up
The proportion of patients with a diag-
nosis of tuberculosis who experienced 
pre-treatment loss to follow-up ranged 
from 4 to 38%.21,34 In studies from Africa 
pre-treatment loss to follow-up ranged 
from 6 to 38%, whereas in studies from 
Asia it ranged from 4 to 28%. Studies 
that reported on data from a single 
clinical site21,22,26,29,31,33,35,40 had higher 
rates of pre-treatment loss to follow-up 
(range: 14–38%) than studies report-
ing on national or regional data (range: 
4–25%).10,23–25,27,28,30,32,34,36–39,41,42
In total, 10 studies10,24,25,30–34,38,40 at-
tempted to trace tuberculosis patients 
with pre-treatment loss to follow-up 
(Table 4). One of them did not detail the 
tracing method used.38 Tracing rates were 
rather poor on average. The proportion of 
patients who could not be traced ranged 
from 0%30 to 77%.32 This limited our abil-
ity to draw inferences about the fate of 
tuberculosis patients with pre-treatment 
loss to follow-up.
Six studies – five of them from 
Asia – reported that patients who had 
initially been classified as being lost to 
follow-up before being treated had in 
fact initiated treatment for tuberculosis 
at another clinical facility.25,31,32,33,34,40 In 
the Asian studies, transfer to a private 
clinic for tuberculosis treatment was the 
commonest reason for pre-treatment loss 
to follow-up; from 0 to 62% of patients 
were found to have been treated at private 
clinics, although only one such study 
successfully traced more than 80% of the 
patients.33 In the only study from Africa 
that traced individuals and recorded if 
they initiated treatment elsewhere, 23% 
of tuberculosis patients who were initially 
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ment in Malawi had started treatment for 
tuberculosis in another district.32
When we counted traced individu-
als who had initiated treatment at an 
alternative site as tuberculosis treatment 
initiators, we noted substantial hetero-
geneity between studies in rates of pre-
treatment loss to follow-up (I2 = 98.4%; 
P < 0.001). This remained after stratify-
ing by study region (Africa: I2 = 96.1%; 
P < 0.001; Asia: I2 = 98.0%; P < 0.001; 
western Pacific: one study only). The 
funnel plot showed asymmetry, sugges-
tive of publication bias (Egger’s statistic: 
P < 0.001). Fig. 3 shows a forest plot for 
the included studies, stratified by region. 
In random-effects meta-analysis, the 
overall inverse-weighted proportion of 
patients with a diagnosis of tuberculosis 
who experienced pre-treatment loss to 
follow-up was 16% (95% confidence 
interval, CI: 13–18). Although this pro-
portion was 18% in studies from Africa 
(95% CI: 13–22) and hence higher than 
in Asian studies, where it was 13% (95% 
CI: 10–15%), the CIs overlapped.
Case fatality
Among traced tuberculosis patients with 
pre-treatment loss to follow-up, the case 
fatality rate ranged from 0% (95% CI: 
0–6)40 to 82% (95% CI: 59–94).10 The 
risk of death was highest in studies from 
Africa but varied widely and low rates 
of tracing rendered it unreliable. Only 
the study from Malawi described the 
time from diagnosis to death among 19 
patients who were traced:10 a median of 
3.5 weeks (range: 2–12) in 14 deceased 
patients.
Reasons for loss to follow-up
Factors associated with an increased risk 
of pre-treatment loss to follow-up were 
male sex, older age,31 living in an urban 
area,25 diagnosis in a hospital or station-
ary clinic (rather than a mobile clinic),23 
geographical location of the tuberculosis 
laboratory (regional versus local),42 and 
being diagnosed with smear-negative but 
culture-positive tuberculosis.24 However, 
distance to treatment site was not associ-
ated with the risk of pre-treatment loss 
to follow-up in Ghana.21
Of the nine studies that traced pa-
tients with pre-treatment loss to follow-
up, one undertook in-depth qualitative 
interviews to determine the reasons for 
drop-out,10 and the other eight were based 
on structured patient interviews, either 
in person24,25,30–32,34,40 or by telephone.33,40 
Health-system-related obstacles for not 
starting treatment for tuberculosis includ-
ed dissatisfaction with long waiting times 
in health services, the need for repeated 
visits, and delays in receiving the results 
of sputum smears.10,25,29,31 Some reasons 
for not starting treatment for tuberculosis 
were patient-related (e.g. difficulty getting 
time off from work or a lack of under-
standing of tuberculosis, its severity or the 
potential benefits of treatment).10,24,31,33,40 
Other reasons were disease-related (e.g. 
weakness and fatigue).31,32
Discussion
This review highlights the paucity of data 
on pre-treatment loss to follow-up among 
patients with a diagnosis of tuberculosis, 
despite high prevalence and mortality 
rates. Only 23 studies from 14 countries 
were identified over a period of 17 years, 
in sharp contrast with the 37 studies on 
HIV care programmes in low-resource 
settings that were published in a period 
of 5 years.43 Yet pre-treatment loss to 
follow-up in patients with smear-positive 
tuberculosis is an important problem for 
tuberculosis programmes because these 
patients are highly infectious44 and expe-
rience high morbidity and mortality.45,46
In the studies identified in this review, 
pre-treatment loss to follow-up was high 
– from 4 to 38% – and was higher in sub-
Saharan Africa (18%) than in Asia (13%). 
Given the very high risk of death among 
tuberculosis patients who are not prompt-
ly treated, minimizing treatment delay 
and losses at all stages in the diagnostic 
and care pathway is critically important.12 
Although tracing was suboptimal in most 
Table 3. Modified Newcastle-Ottawa Scale for assessment of the quality of the studies 
included in the review of pre-treatment loss to follow-up in tuberculosis 
patientsa
Author Country Selectionb Outcomec 
Creek27 Botswana *** **
Dembele28 Burkina Faso *** *
Afutu21 Ghana *** **
Glynn30 Malawi *** ***
Nyirenda32 Malawi *** *
Squire10 Malawi *** **
Uchenna36 Nigeria *** *
Botha23 South Africa *** ***
Botha24 South Africa *** ***
Claassens37 South Africa *** *
Dunbar29 South Africa *** ***
Davis41 Uganda *** *
Chadambuka26 Zimbabwe **
Balasubramanian22 India **
Gopi31 India ** *
Sai Babu34 India *** *
Razia39 Pakistan *** *
Rao33 Pakistan **
Rao40 Pakistan
Korobitsyn38 Tajikistan *** *
Uthaivoravit35 Thailand *** *
Buu25 Viet Nam *** **
Ram42 Fiji *** *
a  A study can be awarded a maximum of one star for each of three items within the “selection” and 
“outcome” categories. 
b  Assessment of patient selection comprised three items (those that score stars are shown): 
(i) representativeness of the cohort (truly representative,* somewhat representative,* selected group 
of users, no description of derivation); (ii) ascertainment of tuberculosis diagnosis (secure records/
registers,* structured interviews,* written self-report, no description); (iii) demonstration that treatment for 
tuberculosis was not being taken at recruitment (secure records/registers,* structured interviews,* written 
self-report, no description). 
c  Assessment of outcome comprised three items (those that score stars are shown): (i) ascertainment of 
pre-treatment loss to follow-up (secure records/registers,* structured interviews,* written self-report, no 
description); (ii) sufficient follow-up time to allow outcome to occur (4 weeks) (yes,* no); (iii) adequacy of 
follow-up (complete*, follow-up > 80%*, follow-up < 80%, no description). 
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studies, the main reason for pre-treatment 
loss to follow-up was death, especially 
in countries in sub-Saharan Africa with 
generalized epidemics of HIV infection, 
perhaps because of the high mortality 
among patients having both tuberculosis 
and HIV infection.47,48 It is difficult to 
ascertain whether these deaths are caused 
by or result from lack of treatment. Only 
one study reported the time between di-
agnosis and death in patients who did not 
start tuberculosis treatment; the median 
of 3.5 weeks found in the study suggests 
that patients were severely ill at the time 
of diagnosis.10
The diagnostic and care pathway is 
often costly and long, even in settings 
where health care and diagnostic tests 
are free at the point of delivery. Reducing 
costs and time for the patient might im-
prove linkage to treatment. Thus, NTPs 
should consider the following measures: 
(i) reducing the number of sputum sam-
ples for initial diagnosis from three to 
two;49 (ii) replacing “spot-morning-spot” 
sputum collection (requiring visits to the 
facility on two separate days) with col-
lection of two spot sputum samples one 
hour apart;14 (iii) preparing two smears 
from the same sputum specimen;50 and 
(iv) introducing same-day light-emitting 
diode (LED) microscopy51 or automated 
nucleic acid molecular diagnostics,52 
shown to be more sensitive and associ-
ated with reduced time to diagnosis and 
lower pre-treatment loss to follow-up. 
Further evaluation of the impact of these 
interventions on reducing pre-treatment 
loss to follow-up is required.
Health system factors, particularly 
relating to the recording and registration 
of suspected and confirmed tuberculo-
sis cases, were found to be important 
contributors to pre-treatment loss to 
follow-up in several studies. Moreover, in 
many studies researchers were required 
to reconcile laboratory registers with 
treatment registers to determine the pre-
treatment loss to follow-up rate, a task 
not easy to perform regularly under rou-
tine programmatic conditions. These is-
sues could be addressed by using a single 
patient identifier for the entire diagnostic 
and care pathway for tuberculosis. Pa-
tients attending a facility with a positive 
screening for symptoms of tuberculosis 
would be recorded in a “cough regis-
ter”53 for subsequent monthly tracing of 
those whose smear results had not been 
received and of smear-positive patients 
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By not including individuals lost 
to follow-up before treatment when 
reporting standard programme indica-
tors, NTPs incorrectly report case de-
tection, cure and case fatality rates. For 
example, with DOTS strategy targets of 
70% case detection and 85% cure rate, 
including individuals who experience 
pre-treatment loss to follow-up (using 
18% in Africa and 13% in Asia, for il-
lustration), would result in the true case 
detection rate rising from 70% to 85% 
in African countries and 70% to 80% in 
Asian countries, as those diagnosed but 
not started on treatment are included 
(Table 5). The cure rate however would 
drop from 85% to 70% in Africa and 
from 85% to 74% in Asia, as those de-
tected but not started on treatment are 
counted as “not cured”. Moreover, in Af-
rican countries, where the higher death 
rate in individuals with pre-treatment 
loss to follow-up could be attributable 
to HIV infection, the reported death 
rate would increase from 6 to 12%. In 
NTPs from Asia, the death rate would be 
unchanged at 3%. These numbers better 
reflect NTP’s actual performance – they 
are finding more cases than thought, but 
are not performing so well at providing 
treatment.
In studies from Asia, where more 
private practitioners offer tuberculosis 
treatment services alongside NTPs,54,55 a 
small number of patients lost to follow-
up initiated treatment with private pro-
viders. Since they would not be included 
in NTP reports of outcomes, the success 
of the national programme would be un-
derestimated. Interventions to improve 
links and data sharing between NTPs 
and private providers have proved effec-
tive in increasing case detection rates in 
studies from Asia56,57 and are promoted 
by WHO.58 Further expansion of such 
interventions will help to ensure that 
programme outcomes are accurately 
reported at the national level.
A limitation of this analysis is the 
poor quality of outcome ascertainment 
in several studies. The small number 
of traced individuals who had initiated 
treatment under a different provider un-
derscores the need to tailor tuberculosis 
services to the individual patient and 
the difficulty of accurately estimating 
outcomes at the programme level. The 
varying length of follow-up of tubercu-
losis patients in cohort studies and the 
absence of time-delineated definitions 
for pre-treatment loss to follow-up make 
it difficult to draw firm conclusions. Fol-
lowing the framework set out in Fig. 1, 
NTPs should strive to adopt and routine-
ly report retention in care throughout the 
diagnostic and care pathway.16,59 A focus 
on retention could enhance the reporting 
of the pre-treatment loss to follow-up rate 
(e.g. the proportion of smear-positive 
patients not initiating treatment for 
tuberculosis within 3 months) as part of 
the regular quarterly reporting system, in 
addition to allowing comparison within 
and between NTPs.
A second limitation is that nega-
tive publication bias may have resulted 
in an under- or overestimation of pre-
treatment loss to follow-up in this review. 
Although we undertook a systematic 
literature search, we may have missed 
some studies reporting on pre-treatment 
loss to follow-up if this was not the main 
focus of the study.
Because the studies identified were 
so heterogeneous, the summary esti-
mates should be interpreted cautiously. 
Our ability to draw conclusions on the 
risk factors or reasons for pre-treatment 
loss to follow-up among people with 
tuberculosis is limited by the poor re-
porting of the baseline characteristics 
of study participants and low numbers 
of traced patients in several studies. We 
identified studies from 8 of the world’s 
22 countries with a high burden of 
tuberculosis. Although the data from 
these countries are helpful in showing the 
important contribution of pre-treatment 
loss to follow-up to suboptimal NTP 
performance, data from a broader range 
of countries and regions are urgently 
needed. In particular, no studies from 
Latin American countries or the Russian 
Federation were identified, perhaps be-
cause these countries have produced no 
studies or because we limited our search 
to English-language sources. To facilitate 
comparisons between studies and re-
gions, all studies reporting outcomes in 
patients with a diagnosis of tuberculosis 
Fig. 3. Proportion of patients with a diagnosis of tuberculosis who were lost to follow-
up before treatmenta in 23 studies from Africa, Asia and the western Pacific
Study ID Proportion (95% CI)b
Africa
Glynn, Malawi: 1986–1994 30 0.06 (0.04–0.08)
Creek, Botswana: 1997 27 0.10 (0.06–0.15)
Nyirenda, Malawi: 1997 32 0.14 (0.13–0.15)
Squire, Malawi: 2000 10 0.15 (0.09–0.20)
Dembele, Burkina Faso: 2001 28 0.13 (0.01–0.25)
Botha, South Africa: 2004–2005 23 0.17 (0.14–0.21)
Botha, South Africa: 2005 24 0.11 (0.07–0.15)
Chadambuka, Zimbabwe: 2006 26 0.27 (0.19–0.35)
Dunbar, South Africa: 2007 29 0.21 (0.16–0.25)
Afutu, Ghana: 2009 21 0.38 (0.28–0.48)
Claassens, South Africa: 2009 37 0.25 (0.23–0.26)
Davis, Uganda: 2009 41 0.23 (0.14–0.33)
Uchenna, Nigeria: 2009 36 0.17 (0.13–0.21)
Asia
Uthaivoravit, Thailand:1995 35 0.21 (0.15–0.26)
Balasubramanian, India: 1998–2001 22 0.14 (0.12–0.17)
Buu, Viet Nam: 2000 25 0.06 (0.05–0.06)
Gopi, India: 2001–2003 31 0.14 (0.12–0.16)
Sai Babu, India: 2006 34 0.04 (0.04–0.05)
Rao, Pakistan: 2007–2008 33 0.25 (0.19–0.31)
Korobitsyn, Tajikistan: 2008–2009 38 0.18 (0.13–0.22)
Razia, Pakistan: 2009 39 0.06 (0.05–0.07)
Rao, Pakistan: 2010 40 0.14 (0.12–0.16)
Western Pacific
Ram, Fiji: 2001–2012 42 0.16 (0.13–0.19)
NOTE: Weights are from random effects analysis
0 0.25 0.5 0.75
CI, confidence interval. 
a All studies combined represent 34 706 patients with a diagnosis of tuberculosis; 3267 were lost to 
follow-up before treatment.
b The 95% CIs were calculated by authors from data provided in selected studies.
Note: In studies in which patients were traced, individuals with a diagnosis of tuberculosis who were lost 
to follow-up before treatment but who had started treatment for tuberculosis elsewhere are included as 
having initiated treatment.
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صخلم
 نم ايندلا ةيحشرلا نادلبو لخدلا ةضفخنلما نادلبلا في لسلا ضىرم في هتعباتم ررقلما جلاعلا لبق ام ةلحرم في نادقفلا
يفصو ليلتحو يجهنم ضارعتسا :ليقثلا ضرلما ءبع تتح حزرت يتلا نادلبلاو طسوتلما لخدلا
 نيذلا لسلا ضىرم في هتعباتم ررقلما نادقفلا مجح مييقت ضرغلا
 ءدب لبق مبه صالخا ةعرزلما وأ ةخاطللا رابتخا جئاتن ةيبايجإ تتبث
.مهعبتت مت نيذلا ضىرلما ينب لئاصلحاو جلاعلا
 وMedline  و  Ovid  تانايب  دعاوق  في  ثحبلا  مت  ةقيرطلا
 نم  ةترفلا  في  اهشرن  مت  يتلا  تاساردلا  نعGlobal Health
 لبق  ام  ةلحرم  في  نادقفلا  تفصو  يتلا  2013  رياني  لىإ  1994
 جئاتن  ةيبايجإ  تتبث  نيذلا  لسلا  ضىرم  في  هتعباتم  ررقلما  جلاعلا
 ةينيتورلا ةينطولا جمابرلا في مبه صالخا ةعرزلما وأ ةخاطللا رابتخا
 ايندلا  ةيحشرلا نادلبو لخدلا  ةضفخنلما  نادلبلا  في لسلا  ةحفاكلم
 .لسلل ليقثلا ءبعلا تتح حزرت يتلا نادلبلاو طسوتلما لخدلا نم
 جلاعلا اؤدبي لم نيذلا ضىرلما ةبسن نأشب تانايبلا صلاختسا متو
 .جاردلإا  يرياعم  تبل  يتلا  تاساردلا  نم  لسلاب  مهصيخشت  دعب
 ءدب  كلذ  في  ماب  ،لئاصلحاو  بابسلأاب  ةينعلما  تانايبلا  يرتح  متو
 مييقت  متو  .ًاحاتم  كلذ  ناك  ماثيح  ،رخآ  قفرم  في  لسلا  جلاع
 تايرثأتلل ةيفصولا تلايلحتلا ءارجإو شرنلا في زيحتلاو ةيرياغتلا
.)ميلقلإا( ةيعرفلا ةئفلا بسح ةيئاوشعلا
 لياجمإ لىع تلمتشا ةلهؤم ةسارد نيشرعو ثلاث ديدتح مت جئاتنلا
 رابتخا جئاتن ةيبايجإ تتبث نيذلا لسلا ضىرم نم ًاضيرم 34706
 في 5و ايقيرفأ  في 8( ًادلب  14  نم مبه ةصالخا ةعرزلما  وأ  ةخاطللا
 تاساردلا مظعم تناكو .)ئدالها طيحلما برغ في ةدحاوو ايسآ
 نادقفلا ديدحتل جلاعلا تلاجسو برتخلما ينب تطبرو ةيعاجترسا
 ةلحرم في نادقفلا حوارتو .هتعباتم ررقلما جلاعلا لبق ام ةلحرم في
 في  ًاعئاش  ناكو  % 38  لىإ  % 4  نم  هتعباتم  ررقلما  جلاعلا  لبق  ام
 ؛% 18  :ةيئاوشعلا  تايرثأتلل  ةحجرلما  ةبسنلا(  ايقيرفأ  تاسارد
should specify the proportion that is lost 
to follow-up before getting treated.
In conclusion, there is a paucity of 
evidence on the magnitude and clinical 
consequences of pre-treatment loss to 
follow-up in tuberculosis patients. The 
limited data available suggest that pre-
treatment loss to follow-up is common 
and that it entails a high risk of death. 
There is an urgent need to improve the 
recording and reporting of pre-treatment 
loss to follow-up and to evaluate and 
scale up interventions to reduce this 
problem. ■
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Table 5. Impact of including rates of pre-treatment loss to follow-up on national tuberculosis programme indicators in hypothetical 




under current  
WHO targets 
After including  
tuberculosis patients 
lost to follow-up  
before treatment
Outcomes reported 
under current  
WHO targets
After including  
tuberculosis patients  
lost to follow-up  
before treatment 
No. of cases 100 000 100 000 100 000 100 000
Cases detected, no. (%) 70 000 (70) 85 366a (85) 70 000 (70) 80 460a (80)
Tuberculosis patients lost to follow-up 
before treatment, no. (%)
Unknown 15 366 (18) Unknown 10 460 (13)
Cases started on treatment, no. (%) Unknown 70 000 (82)b Unknown 70 000 (87)b
Patients cured, no. (%) 59 500 (85) 59 500 (70)c 59 500 (85) 59 500 (74)c
Deceased tuberculosis patients, no. (%) 4200d (6) 12 498e (12) 2100d (3) 3251e (3)
WHO, World Health Organization.
a  Calculated as [1 ÷ (1 − fraction lost to follow-up before treatment)] × number of cases detected. For Africa: [1 ÷ 0.82] × 70 000; for Asia: [1 ÷ 0.87] × 70 000.
b  Percentage calculated as number of cases initiating tuberculosis treatment divided by the number of cases detected. For Africa: 70 000 ÷ 85 366; for Asia: 
70 000 ÷ 80 460.
c  Percentage calculated as the number of patients who successfully completed treatment divided by the number of cases detected. For Africa: 59 500 ÷ 85 366; for 
Asia: 59 500 ÷ 80 460.
d  Number obtained from WHO country database.
e  Calculated as the number of deceased tuberculosis patients plus the product of the number of cases lost to follow-up before treatment and the median case fatality 
rate found in this review. For Africa: 4200 + (15 366 × 0.54); for Asia: 2100 + (10 460 × 0.11).
Note: Estimates for the western Pacific region not included, as only one study was identified.
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结果 确认了 23 个符合要求的研究，其中包括 14 个
国家（非洲 8 个，亚洲 5 个，西太平洋 1 个）的总计
34706 名痰涂片阳性或者菌培阳性肺结核病人。大多
数研究是回顾性研究，与实验室和治疗登记相关，用
以识别治疗前失访情况。治疗前失访率为 4% 到 38%
不等，常见于非洲（随机加权比例 WP ：18% ；95% 置







Le manque de suivi avant le traitement chez les patients atteints de tuberculose dans les pays à revenu faible et à revenu 
moyen inférieur fortement touchés par la maladie: méta-analyse et analyse systématique
Objectif Évaluer l’ampleur du manque de suivi chez les patients atteints 
d’une tuberculose à frottis positif ou culture positive avant le début du 
traitement, ainsi que les résultats chez les patients qui ont été suivis.
Méthodes Des études publiées entre 1994 et janvier 2013, qui décrivaient 
le manque de suivi des patients atteints de tuberculose à frottis positif 
ou à culture positive dans des programmes nationaux courants de lutte 
contre la tuberculose (NTP) dans les pays à revenu faible et à revenu 
moyen inférieur fortement touchés par la tuberculose ont été recherchées 
dans les bases de données Ovid, Medline et Global Health. Des données 
concernant le taux de patients qui n’ont pas débuté le traitement après 
leur diagnostic de tuberculose ont été extraites des études satisfaisant 
les critères d’inclusion. Le cas échéant, les données portant sur les causes 
et les résultats, y compris le début d’un traitement contre la tuberculose 
dans un autre établissement, ont été examinées. L’hétérogénéité et le 
parti pris dans les publications ont été évalués, et des méta-analyses à 
effets aléatoires par sous-groupe (région) ont été réalisées.
Résultats Vingt-trois études éligibles ont été identifiées pour un total 
de 34 706 patients atteints de tuberculose à frottis positif ou à culture 
positive dans 14 pays (8 en Afrique, 5 en Asie et 1 dans le Pacifique 
occidental). La plupart des études étaient rétrospectives et associaient 
des registres de laboratoire et de traitement pour identifier le manque 
de suivi avant le traitement. Celui-ci variait de 4% à 38% et s’est révélé 
commun dans les études provenant d’Afrique (proportion pondérée à 
effets aléatoires, PP: 18%; intervalle de confiance à 95%, IC: 13–22) et 
d’Asie (PP: 13%; IC à 95%: 10–15).
Conclusion Le manque de suivi avant le traitement, commun dans la 
plupart des contextes, peut entraver les efforts fournis en matière de 
lutte contre la tuberculose. Comme les individus qui ne sont pas suivis 
avant le traitement ne sont pas pris en compte lors de l’élaboration des 
rapports sur les indicateurs de programme standard, les programmes 
nationaux de lutte contre la tuberculose sous-estiment les taux de 
dépistage des cas et la mortalité, mais surestiment les taux de guérison.
Резюме
Случаи отсутствия наблюдения до начала лечения больных туберкулезом в странах с низкими 
доходами и доходами ниже среднего уровня, а также в странах с высоким бременем туберкулеза: 
систематический обзор и мета-анализ
Цель Произвести количественную оценку числа случаев 
отсутствия наблюдения за мокрото- или культуропозитивными 
пациентами, страдающими туберкулезом легких, с момента 
диагностирования заболевания до начала лечения, а также 
обработать результаты по пациентам, которых удалось отследить.
Методы В базах данных Ovid, Medline и Global Health был 
произведен поиск исследований, проведенных в рамках 
стандартных национальных программ по борьбе с туберкулезом 
в странах с низкими доходами и доходами ниже среднего 
уровня, а также в странах с высоким бременем туберкулеза, 
опубликованных в период с 1994 года по январь 2013 года, и 
содержащих описания случаев отсутствия наблюдения до начала 
лечения за мокротопозитивными или культуропозитивными 
пациентами, страдающими туберкулезом легких. Данные по 
пропорциональному количеству пациентов, которые не начали 
лечение после диагностирования туберкулеза, были извлечены 
из исследований, соответствующих критериям включения в 
данный анализ. По мере возможности, также были исследованы 
данные по причинам и последствиям, включая прохождение 
лечения в другом медицинском учреждении. Также была 
проведена оценка разнородности и систематических ошибок, 
связанных с предпочтительной публикацией положительных 
результатов исследований, а также мета-анализ случайных 
эффектов по подгруппам (регионам).
 ؛% 13 :ةحجرلما ةبسنلا( ايسآو )22 لىإ 13 نم ،% 95 ةقثلا لصاف
.)15 لىإ 10 نم ،% 95 ةقثلا لصاف
 جلاعلا لبق ام ةلحرم في نادقفلا لقرعي نأ نكملما نم جاتنتسلاا
 ةحفاكم  دوهج  ،تائيبلا  مظعم  في  عيشي  يذلاو  ،هتعباتم  ررقلما
 تلادعم  ريدقت  نم  لسلا  ةحفاكلم  ةينطولا  جمابرلا  للقتو  .لسلا
 ءافشلا تلادعم ريدقت نم ديزتو تايفولاو تلاالحا نع فشكلا
 دنع جلاعلا  لبق مهتعباتم  تدقف نيذلا  صاخشلأا دع مدع دنع
.ةدحولما جمابرلا تاشرؤم نع غلابلإا
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Результаты Было выявлено 23 исследования, соответствующие 
критериям включения в данный анализ, которые охватывали 
в целом 34 706 мокротопозитивных или культуропозитивных 
пациентов, страдающих туберкулезом легких из 14 стран (8 в 
Африке, 5 в Азии и 1 в регионе Западной части Тихого океана). 
Большинство исследований были ретроспективными и включали 
анализ журналов регистраций результатов лабораторных 
анализов и прохождения лечения, что позволило выявить случаи 
непрохождения последующего наблюдения до начала лечения. 
Показатель непрохождения последующего наблюдения до 
начала лечения колебался от 4 до 38%, где наиболее высокие 
значения были отмечены в исследованиях, проводимых в Африке 
(взвешенная пропорция случайных эффектов, ВП: 18%; 95% 
доверительный интервал, ДИ: 13–22) и Азии (ВП: 13%; 95% ДИ: 10–15).
Вывод Непрохождение пациентами наблюдения от момента 
обнаружения заболевания до начала лечения, при схожих 
значениях остальных параметров, может снижать эффект от 
принимаемых мер по борьбе с туберкулезом. Неучет лиц, 
за которыми не велось наблюдение до начала лечения, и 
их невключение в отчеты со стандартными показателями 
программы приводит к тому, что национальные программы по 
борьбе с туберкулезом занижают показатели выявления случаев 
заболевания и смертности, одновременно завышая оценки 
показателей эффективности лечения.
Resumen
Pérdida de seguimiento antes del tratamiento de pacientes con tuberculosis en países de ingresos medios y bajos y en países 
con carga alta: una revisión sistemática y metanálisis
Objetivo Evaluar la magnitud de la pérdida de seguimiento de los 
pacientes con tuberculosis que dieron positivo en el análisis o el cultivo 
antes del inicio del tratamiento y los resultados entre los pacientes que 
se sometieron a un seguimiento.
Métodos Se realizó una búsqueda en las bases de datos Ovid, Medline 
y Global Health de estudios publicados entre 1994 y enero de 2013 que 
describían pérdidas de seguimiento antes del tratamiento en pacientes 
que dieron positivo en el análisis o el cultivo de tuberculosis en los 
programas nacionales contra la tuberculosis (PNT) ordinarios en países 
de ingresos medios y bajos y en países con carga alta de tuberculosis. 
Se extrajeron datos sobre la proporción de pacientes que no inició un 
tratamiento después del diagnóstico de la tuberculosis de estudios 
que cumplían los criterios de inclusión. Siempre que fue posible, se 
investigaron los datos sobre las causas y resultados, incluida la iniciación 
del tratamiento de la tuberculosis en otro centro. Se evaluó el sesgo de 
las publicaciones y la heterogeneidad, y se realizaron metanálisis de 
efectos aleatorios por subgrupos (región).
Resultados Se identificaron veintitrés estudios que cumplían los 
criterios, con un total de 34 706 pacientes que dieron positivo en el 
análisis o cultivo de tuberculosis de 14 países (8 de África, 5 de Asia y 1 
del Pacífico occidental). La mayoría de los estudios eran retrospectivos y 
relacionaban los registros de laboratorio con los registros de tratamiento 
para identificar la pérdida de seguimiento antes del tratamiento, 
que osciló entre el 4 y 38 % y fue frecuente en los estudios de África 
(proporción ponderada de efectos aleatorios, WP: 18 %; intervalo de 
confianza del 95 %, IC: 13–22) y Asia (WP: 13 %; IC del 95 %: 10–15).
Conclusión La pérdida de seguimiento antes del tratamiento, común en 
la mayoría de los entornos, puede obstaculizar los esfuerzos de control 
de la tuberculosis. Sin contar los pacientes cuyo seguimiento se pierde 
antes del tratamiento, los programas nacionales contra la tuberculosis 
subestiman la mortalidad y las tasas de detección de casos, a la vez que 
sobrestiman las tasas de curación al informar sobre los indicadores del 
programa estándar.
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